Dr. Binkui Li is currently a professor, PhD supervisor and deputy director of Liver Surgery Department, Sun Yat-sen University Cancer Center. He specializes in multidisciplinary treatment of liver cancers, including surgery, vascular interventional therapy, targeted and immunotherapy. Dr. Li has devoted himself to improving patients’ curative effects of disease and quality of life by developing a multidisciplinary, individualized, systemic treatment program for every patient. He focuses on conversion therapy for advanced liver cancer, which creates surgery opportunities for some initially unresectable liver cancers. As an expert member of Multi-Disciplinary Team (MDT) for colorectal cancer, Dr. Li is also skilled in surgery of liver metastasis from colorectal cancer. Dr. Li had been a visiting scholar in MD Anderson Cancer Center from 2013 to 2014. In 2018, Dr. Li was awarded the Outstanding Young Medical Talents in Guangdong Province. Besides, he has undertaken researches of National Natural Science Foundation of China, Key projects of Guangdong Provincial Natural Science Foundation, Guangzhou Science and Technology Planning Project, etc.

Pathogenesis of hepatocellular carcinoma; mechanisms of drug resistance towards chemotherapy, targeted therapy and immunotherapy; biomarkers of hepatocellular carcinoma.

Bachelor of Medicine, former Sun Yat-sen University of Medical Sciences, 1996-2001.

Master of Medicine, Sun Yat-sen University Cancer Center, 2001-2003.

Doctor of Medicine, Sun Yat-sen University Cancer Center, 2007-2010.

Selected publications
(1) CpG methylation signature predicts recurrence in early-stage hepatocellular carcinoma: results from a multicenter study. J Clin Oncol 2017; 35(7):734-742.

(2) Mutual regulation of miR-199a-5p and HIF-1α modulates the Warburg effect in hepatocellular carcinoma. J Cancer 2017; 8:940-949.

(3) Nomogram to predict survival of patients with recurrence of hepatocellular carcinoma after surgery. Clin Gastroenterol Hepatol 2018;16:756–764.

(4) Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Aliment Pharmacol Ther 2018; 48(6):671-681.

(5) Long- versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study. Cancer Commun (Lond) 2018;38(1):26.

(6) The efficacy and safety of long- versus short-interval transarterial chemoembolization in unresectable hepatocellular carcinoma. J Cancer 2018;9(21):4000-4008.

(7) Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation. BMC Cancer 2018;18(1):1186.

(8) Extremely high preoperative alpha-fetoprotein level is associated with vascular invasion, non-R0 resection, and poor prognosis in hepatocellular carcinoma patients. Am Surg 2019;85(6):e309-e312.

(9) Resection vs ablation for multifocal hepatocellular carcinomas meeting the Barcelona-Clinic Liver Cancer A Classification: a propensity score matching study. J Cancer 2019;10(13):2857-2867.

(10) Microwave ablation versus resection for hepatocellular carcinoma within the Milan criteria: a propensity-score analysis. Ther Adv Med Oncol 2019; 11: 1-13.

(11) Lipiodol deposition in portal vein tumor thrombus predicts treatment outcome in HCC patients after transarterial chemoembolization. Eur Radiol 2019;29(11):5752-5762.

(12) Comparison of the prognostic value of inflammation-based scores in early recurrent hepatocellular carcinoma after hepatectomy. Liver Int 2020;40(1):229-239.

(13) Dysregulated Sp1/miR-130b-3p/HOXA5 axis contributes to tumor angiogenesis and progression of hepatocellular carcinoma. Theranostics 2020;10(12):5209-5224.

(14) Primary tumor location affects recurrence-free survival for patients with colorectal liver metastases after hepatectomy: a propensity score matching analysis. World J Surg Oncol 2020;18(1):98.

(15) Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study. J Cancer Res Clin Oncol 2020;146(10):2669-2680.

Updated October 2020 by International Office, Sun Yat-sen University Cancer Center